ALCLS — Cellectis SA Share Price
0.000.00%
Last trade - 00:00- €99.49m
- -€47.28m
- $49.22m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.86 | ||
| Price to Tang. Book | 0.87 | ||
| Price to Free Cashflow | 5.91 | ||
| Price to Sales | 2.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.41% | ||
| Return on Equity | -34.08% | ||
| Operating Margin | -121% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 59.56 | 38.6 | 25.73 | 9.19 | 49.22 | 70.97 | 74.63 | 16.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Directors
- Jean-Pierre Garnier NEC (73)
- Andre Choulika CEO (56)
- David Sourdive CFD (54)
- Eric Dutang CFO (47)
- Kyung Nam-Wortman CHO (51)
- Jon Voss EVP (61)
- Leopold Bertea SVP (56)
- Steven Doares SVP (61)
- Mark Frattini SVP
- Philippe Duchateau CSO (58)
- Stephan Reynier CCO (52)
- Marie-Bleuenn Terrier GCN (39)
- Carrie Brownstein EXB (51)
- Arthur Stril EXB (32)
- Laurent Arthaud NID (58)
- Pierre Bastid NID (67)
- Rainer Boehm NID (60)
- Alain Godard NID (75)
- Herve Hoppenot NID (61)
- Annick Schwebig NID (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 2000
- Public Since
- February 6th, 2007
- No. of Employees
- 224
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 72,093,873
- Address
- 8, rue de la Croix Jarry, PARIS, 75013
- Web
- https://www.cellectis.com/
- Phone
- +33 181691600
- Contact
- Arthur Stril
- Auditors
- Ernst & Young et Autres
Upcoming Events for ALCLS
Q1 2025 Cellectis SA Earnings Release
Cellectis SA at Jefferies Global Healthcare Conference
Cellectis SA at Goldman Sachs Global Healthcare Conference
Cellectis SA Annual Shareholders Meeting
Q2 2025 Cellectis SA Earnings Release
Similar to ALCLS
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Eurobio Scientific SA
Euronext - Paris
FAQ
What is the Cellectis SA share price?
As of Today at 19:50 UTC, shares in Cellectis SA are trading at €1.38. This share price information is delayed by 15 minutes.
How has the Cellectis SA share price performed this year?
Shares in Cellectis SA last closed at €1.38 and the price had moved by -42.02% over the past 365 days. In terms of relative price strength the Cellectis SA share price has underperformed the FTSE Global All Cap Index by -43.47% over the past year.
What are the analyst and broker recommendations for Cellectis SA?
The overall consensus recommendation for Cellectis SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cellectis SA dividend yield?
Cellectis SA does not currently pay a dividend.
Does Cellectis SA pay a dividend?
Cellectis SA does not currently pay a dividend.
When does Cellectis SA next pay dividends?
Cellectis SA does not currently pay a dividend.
How do I buy Cellectis SA shares?
To buy shares in Cellectis SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cellectis SA?
As of the previous close price of €1.38, shares in Cellectis SA had a market capitalisation of €99.49m.
Where are Cellectis SA shares listed?
Here are the trading details for Cellectis SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALCLS
What kind of share is Cellectis SA?
Based on an overall assessment of its quality, value and momentum Cellectis SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cellectis SA share price forecast for 2025?
The analyst consensus target price for shares in Cellectis SA is €6.47. That is 368.68% above the last closing price of €1.38.
Analysts covering Cellectis SA currently have a consensus Earnings Per Share (EPS) forecast of -$1.14 for the next financial year.
Find out moreWhat is the trend in the Cellectis SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cellectis SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -21.25%.
As of the last closing price of €1.38, shares in Cellectis SA were trading -17.71% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cellectis SA PE Ratio?
The Cellectis SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €1.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cellectis SA?
Cellectis SA's management team is headed by:
- Jean-Pierre Garnier - NEC
- Andre Choulika - CEO
- David Sourdive - CFD
- Eric Dutang - CFO
- Kyung Nam-Wortman - CHO
- Jon Voss - EVP
- Leopold Bertea - SVP
- Steven Doares - SVP
- Mark Frattini - SVP
- Philippe Duchateau - CSO
- Stephan Reynier - CCO
- Marie-Bleuenn Terrier - GCN
- Carrie Brownstein - EXB
- Arthur Stril - EXB
- Laurent Arthaud - NID
- Pierre Bastid - NID
- Rainer Boehm - NID
- Alain Godard - NID
- Herve Hoppenot - NID
- Annick Schwebig - NID